Retinal Hemorrhage

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2016-08-08
Clinical Trial Update: Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) [Phase 1]
A Phase 1 trial evaluating subretinal Lucentis (ranibizumab) for hemorrhagic age-related macular degeneration has been withdrawn.